A Study to Evaluate the Tolerability, Safety and Efficacy of GNR-097 Gene Therapy in Pediatric Patients With Duchenne Muscular Dystrophy

NCT07673809 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Duchenne Muscular Dystrophy

Interventions

GENETIC: GNR-097
GENETIC: Placebo followed by GNR-097

Sponsor

AO GENERIUM